Biocytogen Pharms (Beijing)

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of novel antibody-based drugs and pre-clinical research services. It operates in China, the United States, and internationally through five segments: Gene-Editing, Pharmacological Efficacy, Model Animals, Antibody Development, and Other. The company offers customized gene editing services, pre-clinical pharmacology services, and breeds and sells animal models. It also develops innovative drugs for oncology and autoimmune diseases, including YH001 and YH002, and has collaborations with Syncromune, Inc., RemeGen Co., Ltd., and Chipscreen NewWay Biosciences. Founded in 2008, it is headquartered in Beijing, China.